Friday, July 10, 2026

pharma · cystic fibrosis · Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)

Théa Pharma Ireland

Théa Pharma Ireland clinical programs — 11 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Castlebar, IE HQ
2018 Founded
19 Employees
EMA registrant Type
Company details
Status
Public
HQ
Castlebar, IE
Founded
2018
Employees
19
Programs
11
Drugs
42
Patents
0
Intelligence · Clinical Programs

Théa Pharma Ireland projects

11 ClinicalTrials.gov programs sponsored by Théa Pharma Ireland.

Théa Pharma Ireland has 11 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. PIPAC_VEROne

    Verona Pharma Ireland Limited

    Gastric adenocarcinoma with peritoneal metastases

    phase 3 small molecule active

    1 trial
  2. SAVE PAIN 2025

    Verona Pharma Ireland Limited

    PARKINSON’S DISEASE WITH MOTOR FLUCTUATIONS

    phase 3 small molecule active

    1 trial
  3. CRCFC-TEICO.SA.2022

    Verona Pharma Ireland Limited

    cystic fibrosis associated to persistent Staphylococcus aureus (including MRSA) infection

    phase 2 small molecule active

    1 trial
  4. INCIPIT

    Verona Pharma Ireland Limited

    multifocal spasticity of the upper and lower limb due to cerebral palsy

    phase 2 small molecule active

    1 trial
  5. PASSION

    Verona Pharma Ireland Limited

    Patients with metastatic PDAC, who have not progressed following completion of at least 16 weeks (can be more) of any multiagent first-line chemotherapy

    phase 2 small molecule active

    1 trial
  6. TAMOXENE 20 mg compresse rivestite con film

    Verona Pharma Ireland Limited

    cystic fibrosis

    phase 2 small molecule active

    1 trial
  7. CRC2024_01

    Verona Pharma Ireland Limited

    Patients with low Vitamin D plasma level

    phase 1 other active

    1 trial
  8. DISCARD

    Verona Pharma Ireland Limited

    Patients with currently remitted depressive disorders.

    approved small molecule active

    1 trial
  9. GR-2021-12373041

    Verona Pharma Ireland Limited

    patients with secondary progressive MS

    approved small molecule active

    1 trial
  10. SIPO20

    Verona Pharma Ireland Limited

    Active progressive multiple sclerosis course after an initial relapse clinical course

    approved small molecule active

    1 trial
  11. Zeposia 0.92 mg hard capsules

    Verona Pharma Ireland Limited

    Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Théa Pharma Ireland have?

11 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.